Myriad Submits sPMA for BRACAnalysis CDx Test

Date : 01/21/2020 @ 12:58PM
Source : Dow Jones News
Stock : AstraZeneca PLC (AZN)
Quote : 50.17  1.23 (2.51%) @ 1:00AM
After Hours
Last Trade
Last $ 50.17 ◊ 0.00 (0.00%)

Myriad Submits sPMA for BRACAnalysis CDx Test

Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart

2 Months : From Dec 2019 to Feb 2020

Click Here for more Myriad Genetics Charts.

By Michael Dabaie


Myriad Genetics Inc. (MYGN) said it submitted a supplementary premarket approval application to the U.S. Food and Drug Administration.

The sPMA is for the company's BRACAnalysis CDx test as a companion diagnostic to AstraZeneca PLC's (AZN) and Merck & Co.'s (MRK) Lynparza for men with metastatic castration-resistant prostate cancer.

AstraZeneca and Merck said Tuesday the supplemental New Drug Application for Lynparza was been accepted and granted priority review by the FDA.

Myriad said the filing for BRACAnalysis CDx is based on the positive clinical results from the PROfound study.


Write to Michael Dabaie at


(END) Dow Jones Newswires

January 21, 2020 07:43 ET (12:43 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Latest AZN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.